Topic Highlight
Copyright ©The Author(s) 2016.
World J Gastroenterol. Jul 28, 2016; 22(28): 6393-6401
Published online Jul 28, 2016. doi: 10.3748/wjg.v22.i28.6393
Table 1 Drugs for hepatitis C virus treatment
Mechanism of actionDrugGenotype
Protease inhibitorTelaprevir1
Boceprevir1
Simeprevir1
Paritaprevir1, 4
Grazoprevir1, 4
Asunaprevir11
ABT-45011
Faldaprevir11
NS5A inhibitorsDaclatasvir1, 3
Ombitasvir1, 4
Ledipasvir1, 4, 5, 6
Elbasvir1, 4
Velpatasvir14
NS5B inhibitors
Nucleotide-analogueSofosbuvir1, 2, 3, 4, 5, 6
Non-nucleoside analogueDasabuvir1
Beclabuvir11
Table 2 Treatments for hepatitis C virus infection
Ref.Treatment, wkGenotypeSVR (total, cirrhotic, non-cirrhotic)Previously treated
Patients included
Davis et al[53]IFN, 2413; NA; NAYes
IFN + RBV, 2430; NA; NA
IDEAL Study Team[54]PEG-IFN/RBV, 48139.8-40.9; 42.1-43.6; 20.7-23.6No
ADVANCE Study Team[48]TVR + PEG-IFN/RBV175; 62-81; 62No
REALIZE Study Team[49]TVR + PEG-IFN/RBV, 48163-64; 28-84; NAYes
SPRINT-2 Investigators[47]BOC + PEG-IFN/RBV, 28167; 70; 50No
BOC + PEG-IFN/RBV, 4868; 70; 50
RESPOND-2 Investigators[46]BOC + PEG-IFN/RBV, 36159; 35; 64Yes
BOC + PEG-IFN/RBV, 4866; 77; 66
PILLAR[55]SMP + PEG-IFN/RBV, 12180.5; NA; 80.5No
SMP + PEG-IFN/RBV, 2486.1; NA; 86.1
Gane et al[56]SOF + RBV, 122 or 3100; NA; 100No
SOF + PEG-IFN/RBV, 8100; NA; 100
COSMOS[57]SMP + SOF + RBV, 241NA; 93;79Yes
SMP + SOF, 24NA; 93; 100
SMP + SOF + RBV, 12NA; 93; 93
SMP + SOF, 12NA; 90; 94
OPTIMIST-1[58]SMP + SOF, 8183; NA; 83Yes
SMP + SOF, 1297; NA; 97
OPTIMIST-2[59]SMP + SOF, 12183; 83; NAYes
AI444040 Study group[60]DCV + SOF, 242 or 3100; NA; NANo
DCV + SOF + RBV, 2486; NA; NANo
DCV + SOF, 241100; NA; NAYes
DCV + SOF + RBV, 2495-100; NA; NA
ALLY-3 Study Team[61]DCV + SOF, 12386-91; 63; 96Yes
ION-2 Investigators[62]LDV + SOF, 12194; 86; 97Yes
LDV + SOF, 2499; 100; 99
LDV + SOF + RBV, 1296; 87; 100
LDV + SOF + RBV, 2499; 100; 99
ION-3 Investigators[63]LDV + SOF, 8194; NA; 94No
LDV + SOF + RBV, 893; NA; 93
LDV + SOF, 1295; NA; 95
MALACHITE-I/II[64]OBV + PTV/r + DSV + RBV, 12197-99; NA; 97-99Yes
PEARL-I[65]OBV + PTV/r491; NA; 91No
OBV + PTV/r + RBV100; NA; 100Yes
SAPPHIRE-II[66]ABT-450/r + OBV + DSV + RBV, 12196.3; NA; 93.6Yes
TURQUOISE-II[67]ABT-450/r + OBV + DSV + RBV, 12191.8; 91.8; NAYes
ABT-450/r + OBV + DSV + RBV, 2495.9; 95.9; NA
ASTRAL-2 and ASTRAL-3[68]SOF + VEL, 12299; 100; 99Yes
395; 93; 98
C-WORTHY[69]GZR + EBR, 12191-97; 91-97; NAYes
GZR + EBR + RBV, 1290-94; 90-94; NA
GZR + EBR, 1894-97; NA; NA
GZR + EBR + RBV, 1897-100; NA; NA
Everson et al[70]DCV + ASV + BCV, 12188.8-89.5; 71.4-100; 87.5-91.1No
DCV + ASV + BCV + RBV, 1285.7; 100; 85
SOUND-2[71]FDV + deleobuvir + RBV, 16159; NA; NANo
FDV + deleobuvir + RBV, 2859-69; NA; NA
FDV + deleobuvir + RBV, 4052; NA; NA
FDV + deleobuvir, 2839; NA; NA